Driven By Herceptin Franchise, Roche Hopes Rituxan Will Follow Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss pharma reported a positive start to the year with its first quarter earnings on April 11, underscoring the strength of its oncology products as it continues to work on lifecycle management.